MOLECULES FOR HEALTH, INC.

Basic Information

800 E. LEIGH STREET
SUITE 206-7
RICHMOND, VA, 23219 1534

Company Profile

n/a

Additional Details

Field Value
DUNS: 106285778
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Ribonucleotide Reductase Inhibitors for Restenosis

    Amount: $225,698.00

    DESCRIPTION (provided by applicant): Coronary artery disease is a major health problem and the leading cause of premature death in the US. Percutaneous coronary intervention with stenting is the prima ...

    SBIR Phase I 2008 Department of Health and Human Services
  2. Radical Scavengers for Brain Ischemia Reperfusion injury

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): The goal of this proposal is to determine the potential of two MFH free radical scavenging compounds, Didox and Imidate, to protect brain tissue from stroke inj ...

    SBIR Phase I 2003 Department of Health and Human Services
  3. Novel Cancer Drugs to Prevent Doxorubicin Toxicity

    Amount: $107,767.00

    DESCRIPTION (provided by applicant): Doxorubicin, an anthracycline drug, is effective against numerous solid and hematological cancers, but cardiotoxicity limits its usefulness. The spe ...

    SBIR Phase I 2001 Department of Health and Human Services
  4. Ribonucleotide Reductase Inhibitors for AIDS Therapy

    Amount: $749,713.00

    We will develop a series of Ribonucleotide reductase inhibitors for the treatment of retrovirus (AIRibonucleotide reductase catalyzes the reductive conversion of ribonucleotides to deoxyribonucleotida ...

    SBIR Phase II 1998 Department of Health and Human Services
  5. Ribonucleotide Reductase Inhibitors for AIDS Therapy

    Amount: $99,794.00

    We will develop a series of Ribonucleotide reductase inhibitors for the treatment of retrovirus (AIRibonucleotide reductase catalyzes the reductive conversion of ribonucleotides to deoxyribonucleotida ...

    SBIR Phase I 1995 Department of Health and Human Services
  6. NEW DRUGS TO PREVENT REPERFUSION ISCHEMIA INJURY

    Amount: $499,963.00

    THIS RESEARCH IS BASED ON THE THESIS THAT OXYGEN-FREE RADICALS CONTRIBUTE IN A SIGNIFICANT WAY TO THE DELETERIOUS ASPECT OF REPERFUSION AFTER A TISSUE OR ORGAN IS DEPRIVED OFOXYGEN AND FLOW IS RE-INIT ...

    SBIR Phase II 1993 Department of Health and Human Services
  7. POTENTIAL NEW TOPICAL ANTI-PSORIASIS AGENTS

    Amount: $49,998.00

    PSORIASIS AFFECTS APPROXIMATELY 2 PERCENT OF THE U. S. POPULATION AND MOST PRESENT TREATMENTS ARE EITHER POTENTIALLY HARMFUL OR ENTAIL DIFFICULT AND/OR UNPLEASANT PROCEDURES. THEREFORE NEW AGENTS ARE ...

    SBIR Phase I 1991 Department of Health and Human Services
  8. NEW DRUGS TO PREVENT REPERFUSION ISCHEMIA INJURY

    Amount: $49,000.00

    N/A

    SBIR Phase I 1990 Department of Health and Human Services
  9. POLYHYDROXYPHENYL-CONJUGATES FOR ANTITUMOR ACTIVITY

    Amount: $49,962.00

    THE REDUCTIVE CONVERSION OF RIBONUCLEOTIDES TO DEOXYRIBONUCLEOTIDES, CATALYZED BY RIBONUCLEOTIDE REDUCTASE,IS A CRUCIAL AND RATE-LIMITING REACTION IN THE DNA BIOSYNTHETIC PATHWAY, AND REPRESENTS A LOG ...

    SBIR Phase I 1989 Department of Health and Human Services
  10. POLYHYDROXYPHENYL DERIVATIVES DESIGNED FOR ANTITUMOR ACTIVITY

    Amount: $50,000.00

    THE REDUCTIVE CONVERSION OF RIBONUCLEOTIDES TO DEOXYRIBONUCLEOTIDES, CATALYZED BY RIBONUCLEOTIDE REDUCTASE,IS A CRUCIAL AND RATE-LIMITING REACTION IN THE DNA BIOSYNTHETIC PATHWAY. THIS REACTION, THERE ...

    SBIR Phase I 1987 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government